Breaking Down Baosheng Science and Technology Innovation Co.,Ltd. Financial Health: Key Insights for Investors

Investors keeping a close eye on Baosheng Science and Technology Innovation Co., Ltd. will want to parse a mix of promising top-line growth and worrying cash and leverage signals: the company posted quarterly revenue of CNY 12.50 billion (down 4.54% YoY) but a trailing twelve-month revenue of CNY 48.57 billion (up 6.50% YoY) against a 2024 annual revenue of CNY 46.36 billion, while profitability paints a bleaker picture with a TTM net loss of CNY 299.9 million and negative EPS of CNY -0.20, margins compressed (gross margin 4.26%, operating margin 0.18%, net margin -0.65%), operating cash flow at negative CNY 166.84 million, and a heavy debt load - total debt of CNY 12.80 billion with debt-to-equity ratios approaching 3.0x and a net debt position of CNY 9.53 billion that combine with an Altman Z-Score of 2.6 and a Piotroski F-Score of 4 to frame heightened solvency risk even as revenue per employee (~CNY 7.50 million) and exposure to aerospace, nuclear, marine and defense end-markets hint at strategic growth avenues worth drilling into-read on to unpack revenue trends, margins, cash flow dynamics, capital structure, valuation metrics (market cap ~CNY 9.3 billion; EV/EBITDA 27.03; P/S ~0.18; P/B ~2.06) and the specific risk factors and opportunities that will determine whether Baosheng can convert its technical positioning into sustainable shareholder value

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Revenue Analysis

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) shows mixed short-term softness with continued multi-year expansion in top-line scale. Key revenue metrics and context are presented below.

• Quarter (Q3 ending 2025-09-30) revenue: CNY 12.50 billion (down 4.54% YoY)
• Trailing twelve months (TTM) revenue: CNY 48.57 billion (up 6.50% YoY)
• Full-year 2024 revenue: CNY 46.36 billion (up 5.85% YoY)
• Workforce: 6,479 employees; revenue per employee ≈ CNY 7.50 million
• Market capitalization: CNY 9.33 billion; P/S ratio: 0.19
• Revenue growth: positive and consistent over the past five years

Implications for investors:

• Valuation: P/S of 0.19 signals market-priced caution versus revenue scale (market cap CNY 9.33B vs TTM revenue CNY 48.57B).
• Operational efficiency: revenue per employee (~CNY 7.50M) points to relatively high productivity for the workforce size.
• Momentum: TTM growth (+6.50%) and five-year positive trend indicate underlying expansion despite the single-quarter dip in Q3 2025.

Further background on the company's history, ownership and business model: Baosheng Science and Technology Innovation Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Profitability Metrics

Key profitability figures for Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) on a trailing twelve months (TTM) basis highlight constrained margins, negative returns, and cash-generation shortfalls. Relevant historical and corporate context can be found here: Baosheng Science and Technology Innovation Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

• Net loss (TTM): CNY 299.9 million; EPS: CNY -0.20.
• Gross profit margin: 4.26% - thin margin at the top line.
• Operating margin: 0.18% - near breakeven at operating level.
• Profit margin: -0.55%; Net profit margin (TTM): -0.65% - overall loss relative to revenue.
• Return on equity (ROE): -5.42% - negative return for shareholders.
• Operating cash flow: CNY -166.84 million - negative cash generation from operations.
• EBITDA margin: 1.42% - very limited cash operating profitability before non-cash and financing items.

• Low gross margin (4.26%) constrains flexibility to absorb cost shocks or invest in growth.
• Operating margin near zero (0.18%) while EBITDA margin is modest (1.42%) - suggests limited buffer before losses at net level.
• Negative operating cash flow (CNY -166.84M) paired with a net loss (CNY -299.9M) signals cash strain and potential reliance on financing or asset sales.
• Negative ROE (-5.42%) and negative EPS reflect shareholder-value erosion during the period.

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Debt vs. Equity Structure

• Total debt: CNY 12.80 billion.
• Debt-to-equity ratio: 2.98 (298.0%).
• Net debt-to-equity ratio: 221.6% - indicates material reliance on debt after cash offsets.
• Five-year trend: debt-to-equity rose from 226.9% to 297.7%, reflecting increasing leverage over time.
• Interest coverage ratio (EBIT / Interest): 0.4x - EBIT covers only 40% of interest expense.
• Operating cash flow: negative - operating cash does not cover debt service.
• Total debt-to-equity ratio reported: 325.83% (alternate aggregate measure showing high debt relative to equity).

• High leverage: multiple ratios above 200% indicate substantial creditor exposure relative to equity.
• Coverage strain: interest coverage of 0.4x and negative operating cash flow point to difficulty servicing interest from core operations.
• Rising trend: the increase in D/E over five years implies growing debt burden rather than deleveraging.

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Liquidity and Solvency

Key short-term liquidity indicators and solvency metrics for Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) provide a mixed picture: sufficient overall current assets relative to current liabilities, constrained immediate liquidity when inventory is excluded, and a meaningful net debt position. Selected quantitative measures below summarize the company's position and implications for investors.

• Current ratio: 1.09 - short-term assets exceed short-term liabilities by ~9%, indicating basic coverage of current obligations.
• Quick ratio: 0.82 - below 1, implying potential difficulty meeting short-term obligations without relying on inventory conversion to cash.
• Net cash position: negative CNY 9.53 billion - company is net indebted rather than net-cash-positive.
• Total cash: CNY 3.27 billion (Cash per share: CNY 2.61) - available liquidity buffer but small relative to total liabilities.
• Altman Z-Score: 2.6 - in the zone signaling increased bankruptcy risk (zone of concern between safe and distressed thresholds).
• Piotroski F-Score: 4 - middling score, suggesting limited operational/financial improvements and a moderate risk profile.

Practical investor considerations:

• Working capital: current ratio >1 provides a basic cushion, but the quick ratio <1 points to reliance on inventory turnover; assess inventory liquidity and turnover days.
• Leverage and cash runway: negative net cash of CNY 9.53 billion means financing costs and refinancing risk are key - review debt maturities and interest coverage in interim reports.
• Risk signals: Altman Z-Score (2.6) flags increased bankruptcy risk while Piotroski F-Score (4) indicates limited operational/financial momentum - reconcile these with recent cash flow trends and management actions.
• Per-share liquidity: CNY 2.61 cash/share provides a tangible but modest buffer; compare to share price and market capitalization for per-share risk assessment.

For broader strategic context and corporate priorities that may affect liquidity planning, see Mission Statement, Vision, & Core Values (2026) of Baosheng Science and Technology Innovation Co.,Ltd.

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Valuation Analysis

Key valuation metrics for Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) reveal mixed signals: high market-based multiples against book and earnings, contrasted with low sales multiple and negative free cash flow. Investors should note valuation extremes and the underlying drivers.

• Market capitalization: CNY 9.27 billion
• Enterprise value (EV): CNY 19.08 billion
• Price-to-book (P/B): 2.06 - market values equity >2x book value
• EV/EBITDA: 27.03 - high valuation relative to operating earnings
• EV/FCF: -46.47 - reflects negative free cash flow (FCF) leading to a negative ratio
• Price-to-sales (P/S): 0.18 - low valuation relative to revenue
• Price-to-tangible book value (P/TBV): 3.25 - higher valuation relative to tangible assets

• Interpretation: High EV/EBITDA and P/TBV suggest investors price in significant growth or superior profitability, while low P/S and negative EV/FCF point to margin, cash-generation, or capital-structure concerns.
• Risks highlighted by these metrics include sensitivity to earnings declines (given high EV/EBITDA) and continued negative FCF that can pressure valuation multiples.

For additional investor context and ownership trends see: Exploring Baosheng Science and Technology Innovation Co.,Ltd. Investor Profile: Who's Buying and Why?

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Risk Factors

• Negative operating cash flow: CNY -166.84 million, signaling potential near-term liquidity stress for operating activities.
• Trailing twelve months (TTM) net profit margin: -0.65%, indicating the company is currently generating losses relative to revenue.
• Total debt: CNY 12.80 billion, with a stated debt-to-equity ratio of 325.83% (and an alternative presentation of 2.98x), reflecting a highly leveraged capital structure.
• Altman Z-Score: 2.6 - in the zone of increased bankruptcy risk compared with healthier firms.
• Piotroski F-Score: 4 - flagged here as indicating a low likelihood of financial distress per the provided guidance.

• Liquidity and cash conversion risk: Sustained negative operating cash flow requires either operational turnaround, asset sales, or external financing to meet working capital and debt servicing needs.
• Refinancing and interest-rate exposure: With CNY 12.8 billion of debt and a high debt-to-equity ratio, the company is exposed to refinancing risk and rising interest costs that could compress margins further.
• Profitability drag: A negative net profit margin (-0.65%) constrains internal capital generation, increasing reliance on external capital and amplifying dilution or covenant risk.
• Default/bankruptcy signalling: An Altman Z-Score of 2.6 places the firm nearer the distress threshold; combined with high leverage, this elevates creditor and covenant default concerns.
• Mixed metric signals: The Piotroski F-Score of 4 (as provided) contrasts with other distress indicators; investors should reconcile these metrics by reviewing underlying accruals, profitability trends, and asset quality.
• Equity risk and volatility: High leverage tends to magnify equity volatility - downside risk to equity holders is accentuated if operating performance fails to stabilize.

Baosheng Science and Technology Innovation Co.,Ltd. (600973.SS) - Growth Opportunities

• End-market exposure: direct participation in aerospace, nuclear, marine engineering and military applications - sectors with high technical entry barriers and long procurement cycles that favor established, qualified suppliers.
• International reach: exports to ~40 countries and operations across Greater China, enabling diversification of demand and pricing power in premium segments.
• High-specification product focus: a strategic tilt toward specialized alloys, components and processing services that command higher ASPs and provide partial insulation from commodity-grade cyclicality.
• Innovation leverage: sustaining competitiveness requires ongoing capex and R&D, creating potential upside if product mix shifts toward new certified applications or higher-margin custom work.

• Valuation signal: a P/B of 2.06 implies the market prices a premium over book value consistent with intellectual capital, certification status and long-term contracts; conversely, a low P/S of 0.18 suggests sales are large relative to equity valuation, pointing to potential upside if margin expansion or profit conversion improves.
• Strategic priorities that could unlock value:
  • Expand certified product lines for aerospace and nuclear suppliers to capture higher ASPs.
  • Grow high-value export channels in existing ~40-country footprint through localized services or partnerships.
  • Invest selectively in automation and metallurgical R&D to reduce unit costs while accelerating time-to-qualification for new customers.
• Risks tied to the upgrade path: sustained capital intensity for qualification cycles, sensitivity to defense procurement timing, and the need to protect margins versus lower-cost competitors.